News
Trastuzumab deruxtecan FDA approval in metastatic NSCLC
Oncologyme
/ Mar 26, 2023
On August 11, 2022, the FDA approved #fam-trastuzumab deruxtecan-nxki (5.4 mg/kg IV every 3 weeks) for adult patients with have...
GIM-2 trial
Oncologyme
/ Mar 26, 2023
In the phase III, GIM-2 study that was presented by Del Mastro el al, #dose_dense chemotherapy significantly improved DFS and...
KEYLYNK-010 trial
Oncologyme
/ Mar 26, 2023
In the randomized KEYLYNK-010 study presented by Dr. Evan Yu, #Pembrolizumab + #olaparib (P+O) failed to improve rPFS or OS...
FDA approval of bevacizumab biosimilar
Oncologyme
/ Feb 15, 2023
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
DATA trial
Oncologyme
/ Feb 15, 2023
In the phase III, DATA study that was presented by Tjan-Heijnen el al, #extended_adjuvant endocrine therapy failed to improve the...
SOLO1 trial
Oncologyme
/ Feb 15, 2023
The latest OS analysis of phase III SOLO1 trial was presented in #ESMO2022 supporting the use of maintenance #olaparib in...
RATIONALE-301 trial
Oncologyme
/ Feb 15, 2023
In the non-inferiority, RATIONALE-301 study presented by Dr. Masatoshi Kudo, Single agent Tislelizumab (TIS), an anti-PD-1 monoclonal antibody, showed comparable...
TROPICS-2 trial
Oncologyme
/ Feb 15, 2023
In the phase III, TROPICS-2 study presented by Hope Rugo el al, #Sacituzumab_govitecan (SG) significantly improved OS (median 14.4 vs...
PAOLA – 1 trial
Oncologyme
/ Feb 15, 2023
The final Overall survival analysis data from the phase III PAOLA – 1 study presented by Ledermann showed that the...
IMmotion 010 trial
Oncologyme
/ Feb 15, 2023
In the IMmotion 010 study presented by Dr. Axel Bex, atezolizumab (anti-PD-L1) monotherapy was studied as adjuvant therapy in patients...
.png)